Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1CNS 1

Conditions

Neoplasm Metastasis 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Mantle-Cell 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Spinocerebellar Degenerations 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Prostatic Neoplasms 1Osteosarcoma 1Neuroblastoma 1Metastatic Castration-resistant Prostate Cancer 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma 1Colonic Neoplasms 1Brain Neoplasms 1

Interventions

Ifosfamide 5Temozolomide 4surufatinib 2irinotecan sucrosofate 2Vincristine 2Radiotherapy 2Nivolumab 2Irinotecan 2Gemcitabine 2Etoposide 2Doxorubicin 2vactosertib 1temsirolimus 1talazoparib 1silmitasertib 1selinexor 1regorafenib 1pepinemab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1pazopanib 1olaparib 1lutetium Lu 177 dotatate 1liposomal doxorubicin 1lenvatinib 1etoposide phosphate 1endostar protein 1dostarlimab 1dinutuximab 1copanlisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Osteosarcoma × copanlisib × Clear all
NCT03458728 2023-12-04

Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

Bayer

Phase 1/2 Terminated
31 enrolled 17 charts
CNSLymphoidSarcoma

Lymphoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡